INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 48m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
Public company

CRISPR Therapeutics AG

CRSPCIK 0001674416

EDGAR filingsOpen in network
Price$50.07
1 year-12.1%
Disclosed transactions1
Buys / sells0 / 1
Max Insider Score26
Connections with evidence2

CRSP · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
26
ARK Investment Management LLC13F filer
CRSPCRISPR Therapeutics AG
TRIM
SELL$101.05M
1.85M sh
Not disclosed

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Holdsevidence
    ARK Investment Management LLC3.4% of reported portfolio · Aug 14, 2026
Aug 14, 2026
quarterly
SEC 13F

Evidence

Lobbying

$0 reported · de-duplicated
2026 Q3 $0 via firms2026 Q2 $0 via firms2026 Q1 $0 via firms
  • In-house report—2026 Q3 · posted Nov 6, 2026 ·
  • In-house report—2026 Q1 · posted Aug 26, 2026 ·
  • In-house report—2026 Q2 · posted Aug 26, 2026 ·

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.